{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:57:35Z","timestamp":1795067855346,"version":"4.10.2"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[1999,9,1]],"date-time":"1999-09-01T00:00:00Z","timestamp":936144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Diagn Lab Immunol"],"published-print":{"date-parts":[[1999,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>To determine the mechanism of the purified protein derivative (PPD)-specific hyporesponsiveness in<jats:italic>Mycobacterium bovis<\/jats:italic>BCG-vaccinated human T-cell leukemia virus type 1 (HTLV-1)-infected individuals, we examined cytokine production in response to PPD in the following four groups of individuals: (i) HTLV-negative, PPD nonresponders (<jats:italic>n<\/jats:italic>= 11; NN); (ii) HTLV-negative, PPD responders (<jats:italic>n<\/jats:italic>= 18; NP); (iii) HTLV-positive, PPD nonresponders (<jats:italic>n<\/jats:italic>= 15; PN); and (iv) HTLV-positive, PPD responders (<jats:italic>n<\/jats:italic>= 15; PP). In vitro stimulation with PPD resulted in both proliferative responses and gamma interferon (IFN-\u03b3) production in NP and PP (<jats:italic>P<\/jats:italic>&lt; 0.02), with minimal proliferation and IFN-\u03b3 production in the NN and PN groups. Further, PPD-specific interleukin 10 (IL-10) production was significantly reduced in the PN group (<jats:italic>P<\/jats:italic>&lt; 0.01), while the other groups had comparable levels. Cytokine reconstitution experiments demonstrated that while addition of recombinant IL-12 (rIL-12) plus anti-IL-4 restored PPD-specific responses in the NN group, it had no effect in the PN group. However, addition of rIL-12 resulted in the increased production of IFN-\u03b3 in both nonresponder groups (NN and PN), suggesting that the lack of IFN-\u03b3 production was not responsible for the PPD anergy. We conclude that PPD-specific anergy in HTLV-1-infected individuals appears to be due in part to their inability to respond to rIL-12.<\/jats:p>","DOI":"10.1128\/cdli.6.5.713-717.1999","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T19:23:21Z","timestamp":1577820201000},"page":"713-717","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Modulation of T-Cell Responses to a Recall Antigen in Human T-Cell Leukemia Virus Type 1-Infected Individuals"],"prefix":"10.1128","volume":"6","author":[{"given":"Muneou","family":"Suzuki","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Retrovirus Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia1;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene S.","family":"Dezzutti","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Retrovirus Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia1;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Okayama","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Second Department of Internal Medicine, Miyazaki Medical College, 5200 Kihara, Miyazaki, Japan2; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Tachibana","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Second Department of Internal Medicine, Miyazaki Medical College, 5200 Kihara, Miyazaki, Japan2; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Tsubouchi","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Second Department of Internal Medicine, Miyazaki Medical College, 5200 Kihara, Miyazaki, Japan2; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Mueller","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Harvard School of Public Health, Harvard University, Boston, Massachusetts3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu B.","family":"Lal","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Retrovirus Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia1;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/383787a0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.1.138"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/515311"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230805"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304223281608"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.4049\/jimmunol.157.3.1288","article-title":"Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands.","volume":"157","author":"Lal R. B.","year":"1996","unstructured":"Lal R. B. Rudolph D. L. Dezzutti C. S. Linsley P. S. Prince H. E. Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands. J. Immunol. 157 1996 1288 1296","journal-title":"J. Immunol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112715"},{"key":"e_1_3_2_9_2","unstructured":"Mueller N. Tachibana N. Stuver S. O. Okayama A. Ishizaki J. Shishime E. Murai K. Shioiri S. Tsuda K. Epidemiologic perspectives of HTLV-I Human retrovirology: HTLV. Blattner W. 1990 281 293 Raven Press New York N.Y"},{"key":"e_1_3_2_10_2","first-page":"1006","article-title":"Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers.","volume":"3","author":"Murai K.","year":"1990","unstructured":"Murai K. Tachibana N. Shioiri S. Shishime E. Okayama A. Ishizaki J. Tsuda K. Mueller N. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J. Acquired Immune Defic. Syndr. 3 1990 1006 1009","journal-title":"J. Acquired Immune Defic. Syndr."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.1.3.273-282.1994"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910420605"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2964.2964"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240460405"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.59.4.505"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910560307"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112459"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.4049\/jimmunol.142.7.2279","article-title":"Human T cell leukemia\/lymphoma virus type I infection of a CD4+ proliferative\/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells.","volume":"142","author":"Yssel H.","year":"1989","unstructured":"Yssel H. Malefyt R. D. W. Dodon M. D. Blanchard D. Gazzolo L. de Vries J. E. Spits H. Human T cell leukemia\/lymphoma virus type I infection of a CD4+ proliferative\/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells. J. Immunol. 142 1989 2279 2284","journal-title":"J. Immunol."}],"container-title":["Clinical Diagnostic Laboratory Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.6.5.713-717.1999","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.6.5.713-717.1999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:18:20Z","timestamp":1695568700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CDLI.6.5.713-717.1999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["10.1128\/CDLI.6.5.713-717.1999"],"URL":"https:\/\/doi.org\/10.1128\/cdli.6.5.713-717.1999","relation":{},"ISSN":["1071-412X","1098-6588"],"issn-type":[{"value":"1071-412X","type":"print"},{"value":"1098-6588","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,9]]},"assertion":[{"value":"1999-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}